Novogen (NASDAQ:KZIA) Downgraded by Wall Street Zen to Hold

Wall Street Zen lowered shares of Novogen (NASDAQ:KZIA) from a buy rating to a hold rating in a research note issued to investors on Sunday morning.

Several other brokerages have also issued reports on KZIA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a research report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Novogen in a research note on Wednesday, January 28th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $19.00.

Novogen Stock Performance

Shares of Novogen stock opened at $8.25 on Friday. Novogen has a 1 year low of $2.86 and a 1 year high of $17.40. The business has a 50-day moving average of $6.67 and a two-hundred day moving average of $7.77.

About Novogen

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.